Patents Assigned to Quest Diagnostics
  • Publication number: 20170328909
    Abstract: The present invention provides aptamers that specifically bind to the EGF receptor in a sample, and diagnostic and analytical methods using those aptamers. In some embodiments, the aptamers include a 3? cap. In some embodiments, the 3? cap is an inverted deoxythymidine. In some embodiments the aptamers include a spacer and at least one moiety selected from the group consisting of binding pair member and a detectable label, wherein the spacer is attached to the 5?-end of the aptamer and the moiety is attached the 5? end of the spacer. In some embodiments the spacer is hexaethylene glycol. In some embodiments, the binding pair member biotin. In some embodiments the detectable label is a fluorophore.
    Type: Application
    Filed: May 5, 2017
    Publication date: November 16, 2017
    Applicants: Quest Diagnostics Investments Incorporated, SOMALOGIC, INC.
    Inventors: Chris Bock, Deborah Ayers, Malti P. Nikrad, Bharat Nathu Gawande, Jennifer C. Bertino, Weimin Sun, Charles M. Strom, Noh Jin Park
  • Patent number: 9817005
    Abstract: Methods are described for determining the amount of metabolites of leflunomide in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying teriflunomide in a sample.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: November 14, 2017
    Assignee: Quest Diagnostics Ivestments Incorporated
    Inventor: Karin O. Thomassian
  • Publication number: 20170316149
    Abstract: DNA variants may be classified according to a rules-based scoring system into five categories that include pathogenic, likely pathogenic, variant of unknown significance, likely benign, and benign. Scores may be associated with variants in a framework that weighs evidence from prediction tools, population frequency, co-occurrence, segregation, and functional studies. A standardized scoring system for assessing pathogenicity may provide reliable, consistent pathogenicity scores for DNA variants encountered in a clinical laboratory setting.
    Type: Application
    Filed: April 28, 2017
    Publication date: November 2, 2017
    Applicant: Quest Diagnostics Investments Inc.
    Inventor: Glenn A. Maston
  • Publication number: 20170306410
    Abstract: The present invention is based on BCR-ABL1 splice variants which result from insertion and/or truncation of the bcr-abl1 transcript and the finding that these variants provide resistance to kinase domain inhibitors such as imatinib, nilotinib and dasatinib.
    Type: Application
    Filed: February 10, 2017
    Publication date: October 26, 2017
    Applicant: Quest Diagnostics Investments Incorporated
    Inventor: Wanlong Ma
  • Patent number: 9797018
    Abstract: Disclosed is a method for determining the presence of Mycobacterium avium complex nucleic acids in a biological sample. In particular, the mig gene of M. avium and the DT1 gene of M. intracellulare are detected, preferably following amplification. In addition, the method distinguishes between species of M. avium and M. intracellulare. Also described are oligonucleotides that can be used as primers to amplify target genes such as mig and DT1 genes and as probes as well as kits containing the oligonucleotide.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: October 24, 2017
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Edgar Ong, Maurice Exner
  • Publication number: 20170292868
    Abstract: An apparatus and method are provided to evaluate an amount of a biological sample in a specimen container. A fixture has a bottom surface configured to support a specimen container. A reference indicator is disposed at a predetermined height relative to the bottom surface. The reference indicator is configured to facilitate a visual comparison of the reference indicator with a height of a volume of a biological sample in the specimen container.
    Type: Application
    Filed: September 16, 2015
    Publication date: October 12, 2017
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Christine AMENDT, Sevag BEDROSIAN, Gordon LOVE, Mkrtich DANIYELYAN, Miguel TORRERO
  • Patent number: 9783854
    Abstract: Provided herein are methods and compositions for detection of a nucleic acid target in a sample. The methods and compositions use primer directed amplification in conjunction with nucleic acid fragmentation. The methods have high sensitivity even in the presence of a large amount of non-target nucleic acid. Also provided are oligonucleotides and kits useful in the method. Exemplary nucleic acid targets are those with mutant gene sequence such as mutant sequence of the EGFR, APC, TMPRSS2, ERG and ETV1 genes.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: October 10, 2017
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Heather R. Sanders, Kevin Z. Qu, Charles M. Strom, Richard A. Bender
  • Publication number: 20170275693
    Abstract: The present invention provides methods for analyzing large nucleic acids including chromosomes and chromosomal fragments. In one aspect, the present invention provides a method of nucleic acid analysis comprising the steps of (a) obtaining a sample of nucleic acid comprising at least one chromosome or fragment greater than about 1 000 base pairs in length and containing a target region; (b) creating an emulsion in which each drop of the emulsion contains an average of between about 0-2, 0-1.75, 0-1.5, 0-1.0, 0-0.75, 0-0.5, or fewer chromosomes or fragments of step (a), (c) performing emulsion PCR, (d) quantifying the number of emulsion droplets containing amplified nucleic acid from the target region; (e) calculating the ratio of droplets containing amplified nucleic acid from the target region to total droplets; and (f) comparing the ratio of step (e) to a reference ratio representing a known genotype.
    Type: Application
    Filed: March 10, 2017
    Publication date: September 28, 2017
    Applicant: Quest Diagnostics Investments Incorporated
    Inventor: Charles M. Strom
  • Publication number: 20170268043
    Abstract: Disclosed are methods for identifying the presence or absence of a target nucleic acid from one or more organisms in a biological sample, said method comprising: (a) spinning the sample at a rotational velocity sufficient to pellet cellular debris and fluorescence inhibitors present within the sample and reduce fluorescence interference or quenching in the sample; and (b) directly amplifying and detecting the target nucleic acid in the sample.
    Type: Application
    Filed: November 24, 2015
    Publication date: September 21, 2017
    Applicant: Quest Diagnostics Inverstments Incorporated
    Inventors: Lucien Jacky, Albert Castro, Peter Lee, Jose Matud, Michelle Tabb
  • Publication number: 20170262166
    Abstract: Computer systems and methods may display multi-dimensional data sets in a dynamically-generated ocular view, which may show the relationship between data points in the different dimensions. For example, such a data set may include in one dimension results of one or more laboratory tests and, in another dimension, body systems or functions that the respective tests may relate to. The ocular view may depict the relationships between the tests and the systems. By being generated dynamically, moreover, the ocular view may be able to present this information for arbitrary sets of test results, without a template having been generated in advance to specify the layout of some particular combination of results.
    Type: Application
    Filed: May 30, 2017
    Publication date: September 14, 2017
    Applicant: Quest Diagnostics Investments Inc.
    Inventors: Peter Wilkinson, Kerry O'Briean
  • Patent number: 9733249
    Abstract: The invention provides compositions and methods for diagnosing a patient as having a myeloproliferative disease by identifying mutations in the MPL gene or gene products.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: August 15, 2017
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Wanlong Ma, Maher Albitar
  • Publication number: 20170214825
    Abstract: Systems and methods are provided though which a transaction, e.g., in a multi-tier, distributed application may be initiated from a portable or hand-held device, such as a smartphone. A computer system or systems, possibly remote from the device, may approve the transaction, complete it, or both, and the remote computer system or systems may cause a document to be printed, e.g., by a printer physically proximate to the device. Aspects of the invention are illustrated by embodiments in which a drug prescription may be created electronically using a hand-held device. In such an embodiment, the prescription may be transmitted to one or more remote computer systems, such as an application server, for processing. If specified, the remote computer systems may cause a prescription to be printed, e.g., at a printer near the prescriber's location. The prescriber may sign the printed prescription and give it to a patient or pharmacy.
    Type: Application
    Filed: April 10, 2017
    Publication date: July 27, 2017
    Applicant: Quest Diagnostics Investments Inc.
    Inventor: John Koehl
  • Publication number: 20170191116
    Abstract: Described herein are methods for direct detection of microbial agent(s) in a polymicrobial sample, such as a biological sample from a human, without culturing the microbial agent(s). The direct detection can identify mixtures of bacteria and/or fungi in the sample. Also described are primer sequences and amplification techniques for performing the direct detection methods.
    Type: Application
    Filed: June 4, 2015
    Publication date: July 6, 2017
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Erik P. Johnson, Nik Isely, Jamie L. Platt, Martin Siaw, Ron M. Kagen, Dale A. Schwab
  • Publication number: 20170191135
    Abstract: Disclosed herein is a combination of genomic sequences whose methylation patterns have utility for the improved detection and differentiation between colorectal neoplasms. Further disclosed herein are methods, nucleic acids and kits for detecting or differentiating between colorectal neoplasms.
    Type: Application
    Filed: June 3, 2015
    Publication date: July 6, 2017
    Applicants: Quest Diagnostics Investments Incorporated, CLINICAL GENOMICS PTY LTD
    Inventors: Susanne Pedersen, Lawrence LaPointe, Rohan Baker, Amber C. Donahue, Yen-lin Peng, Frederic Waldman
  • Patent number: 9696325
    Abstract: The invention relates to the detection of DHA and EPA. In a particular aspect, the invention relates to methods for detecting DHA and EPA by mass spectrometry and kits for carrying out such methods.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: July 4, 2017
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Scott M. Goldman, Julie A. Neidich
  • Publication number: 20170175198
    Abstract: Provided herein are methods for detecting and discriminating BRAF V600 mutations. Also provided herein are methods for diagnosis, prognosis, management, and treatment decisions of BRAF V600 mutation-related diseases or conditions.
    Type: Application
    Filed: February 20, 2015
    Publication date: June 22, 2017
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Amber C. Donahue, Yen-lin Peng
  • Patent number: 9685311
    Abstract: Provided are methods for determining the amount of reverse T3 in a sample using mass spectrometry. The methods generally involve ionizing reverse T3 in a sample and detecting and quantifying the amount of the ion to determine the amount of reverse T3 in the sample.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: June 20, 2017
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: J. Fred Banks, Peter P. Chou, Noriya M. Matt
  • Patent number: 9678087
    Abstract: Provided are methods for determining the amount of estrone in a sample using mass spectrometry. The methods generally involve ionizing estrone in a sample and detecting and quantifying the amount of the ion to determine the amount of estrone in the sample.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: June 13, 2017
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Mildred M. Goldman, Richard E. Reitz
  • Patent number: 9678635
    Abstract: Computer systems and methods may display multi-dimensional data sets in a dynamically-generated ocular view, which may show the relationship between data points in the different dimensions. For example, such a data set may include in one dimension results of one or more laboratory tests and, in another dimension, body systems or functions that the respective tests may relate to. The ocular view may depict the relationships between the tests and the systems. By being generated dynamically, moreover, the ocular view may be able to present this information for arbitrary sets of test results, without a template having been generated in advance to specify the layout of some particular combination of results.
    Type: Grant
    Filed: December 31, 2012
    Date of Patent: June 13, 2017
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Peter Wilkinson, Kerry O'Brien
  • Publication number: 20170152572
    Abstract: Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g., translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5? and 3? regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5? portion of a target gene relative to the 3? region of the target gene.
    Type: Application
    Filed: December 8, 2016
    Publication date: June 1, 2017
    Applicant: Quest Diagnostics Investment Incorporated
    Inventors: Heather R. Sanders, Maher Albitar, Aurelia Meloni-Ehrig